Skip to content
    CollabAI
    PharmaAI
    PharmaAI by CollabAI · Regulatory Affairs

    AI That Reviews FDA Documents Faster Than Your Legal Team — At 1% of the Cost

    Upload any FDA submission, drug label, or protocol document — the Regulatory Doc Validator checks every section against current FDA/EMA/ICH guidelines, flags non-compliant language, and generates a correction report with cited references.

    FDA EMA ICH 21 CFR Part 11
    $40K
    Saved Per Submission
    4 hrs vs 4 wks
    Review Turnaround
    Zero
    Missed Citations

    Why Regulatory Review Is Broken

    $2,000/hour legal review

    Pharma companies pay specialist regulatory lawyers $2,000/hour to manually verify FDA submission documents. A single label review costs $40,000–80,000.

    Guideline changes catch teams off guard

    FDA guidelines update constantly. A label approved 2 years ago may now be non-compliant with new draft guidance. Manual tracking is impossible at scale.

    Submission rejections delay drug launches

    A Complete Response Letter from FDA for a labeling issue can delay a drug launch by 6–12 months and cost $100M+. AI catches these before submission.

    How It Works

    1

    Upload Document

    FDA submission, drug label, protocol, SOP, or any regulatory document.

    2

    Guideline Mapping

    AI maps each section to applicable FDA/EMA/ICH guidance documents.

    3

    Compliance Check

    Flags non-compliant language with exact guideline citations.

    4

    Correction Report

    Generates a redline report with suggested replacements and references.

    Inside the Validator

    regdoc.ai/upload
    DEMO
    DRUGX_Label_v3.2.pdf
    Analyzing — 78%
    Indications
    Dosage
    Warnings
    Contraindications...
    regdoc.ai/issues/DRUGX_Label_v3.2
    DEMO
    ● CRITICAL — Section 5.1 Warnings
    Black box warning format does not comply with 21 CFR §201.57(c)(1). Missing required border formatting.
    ● MAJOR — Section 6.1 Adverse Reactions
    Incidence table missing required MedDRA SOC grouping per FDA guidance 2024.
    ● MINOR — Section 12.3 Pharmacokinetics
    Missing population PK study reference recommended per EMA/CHMP.
    regdoc.ai/redline
    DEMO
    ORIGINAL
    WARNING: May cause serious cardiovascular events. Use with caution.
    CORRECTED
    ━━ BOXED WARNING ━━ Serious cardiovascular events have been reported. See full prescribing information.
    📖 Guideline: 21 CFR §201.57(c)(1) — FDA Labeling Guidance 2024

    Features

    FDA 21 CFR §201 label compliance

    ICH M4/M4E CTD format validation

    EMA CHMP guideline mapping

    Automatic redline generation

    Cited reference library

    Version comparison (track changes)

    Cut your regulatory review costs by 99%.

    Cookie Settings

    We use cookies to enhance your experience, analyze site traffic and deliver personalized content. Privacy Policy.